202 related articles for article (PubMed ID: 28009435)
1. Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.
Fuh FK; Looney C; Li D; Poon KA; Dere RC; Danilenko DM; McBride J; Reed C; Chung S; Zheng B; Mathews WR; Polson A; Prabhu S; Williams M
Br J Pharmacol; 2017 Apr; 174(8):628-640. PubMed ID: 28009435
[TBL] [Abstract][Full Text] [Related]
2. In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.
Zheng B; Fuji RN; Elkins K; Yu SF; Fuh FK; Chuh J; Tan C; Hongo JA; Raab H; Kozak KR; Williams M; McDorman E; Eaton D; Ebens A; Polson AG
Mol Cancer Ther; 2009 Oct; 8(10):2937-46. PubMed ID: 19808977
[TBL] [Abstract][Full Text] [Related]
3. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.
Li D; Lee D; Dere RC; Zheng B; Yu SF; Fuh FK; Kozak KR; Chung S; Bumbaca Yadav D; Nazzal D; Danilenko D; Go MAT; Williams M; Polson AG; Poon KA; Prabhu S
Br J Pharmacol; 2019 Oct; 176(19):3805-3818. PubMed ID: 31270798
[TBL] [Abstract][Full Text] [Related]
4. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.
Pfeifer M; Zheng B; Erdmann T; Koeppen H; McCord R; Grau M; Staiger A; Chai A; Sandmann T; Madle H; Dörken B; Chu YW; Chen AI; Lebovic D; Salles GA; Czuczman MS; Palanca-Wessels MC; Press OW; Advani R; Morschhauser F; Cheson BD; Lenz P; Ott G; Polson AG; Mundt KE; Lenz G
Leukemia; 2015 Jul; 29(7):1578-86. PubMed ID: 25708834
[TBL] [Abstract][Full Text] [Related]
6. An Anti-CD22-
Yu SF; Lee DW; Zheng B; Del Rosario G; Leipold D; Booler H; Zhong F; Carrasco-Triguero M; Hong K; Yan P; Rowntree RK; Schutten MM; Pillow T; Sadowsky JD; Dragovich PS; Polson AG
Mol Cancer Ther; 2021 Feb; 20(2):340-346. PubMed ID: 33273056
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.
Polson AG; Williams M; Gray AM; Fuji RN; Poon KA; McBride J; Raab H; Januario T; Go M; Lau J; Yu SF; Du C; Fuh F; Tan C; Wu Y; Liang WC; Prabhu S; Stephan JP; Hongo JA; Dere RC; Deng R; Cullen M; de Tute R; Bennett F; Rawstron A; Jack A; Ebens A
Leukemia; 2010 Sep; 24(9):1566-73. PubMed ID: 20596033
[TBL] [Abstract][Full Text] [Related]
8. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Li D; Poon KA; Yu SF; Dere R; Go M; Lau J; Zheng B; Elkins K; Danilenko D; Kozak KR; Chan P; Chuh J; Shi X; Nazzal D; Fuh F; McBride J; Ramakrishnan V; de Tute R; Rawstron A; Jack AS; Deng R; Chu YW; Dornan D; Williams M; Ho W; Ebens A; Prabhu S; Polson AG
Mol Cancer Ther; 2013 Jul; 12(7):1255-65. PubMed ID: 23598530
[TBL] [Abstract][Full Text] [Related]
9. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.
Polson AG; Yu SF; Elkins K; Zheng B; Clark S; Ingle GS; Slaga DS; Giere L; Du C; Tan C; Hongo JA; Gogineni A; Cole MJ; Vandlen R; Stephan JP; Young J; Chang W; Scales SJ; Ross S; Eaton D; Ebens A
Blood; 2007 Jul; 110(2):616-23. PubMed ID: 17374736
[TBL] [Abstract][Full Text] [Related]
10. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.
Rossi EA; Goldenberg DM; Michel R; Rossi DL; Wallace DJ; Chang CH
Blood; 2013 Oct; 122(17):3020-9. PubMed ID: 23821660
[TBL] [Abstract][Full Text] [Related]
11. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
13. Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.
Leung SO; Gao K; Wang GY; Cheung BK; Lee KY; Zhao Q; Cheung WT; Wang JZ
MAbs; 2015; 7(1):66-76. PubMed ID: 25427174
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
Shor B; Gerber HP; Sapra P
Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
[TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review].
Lu PP; Meng ZY; Zhou MX; Wang MW; Dou GF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1258-61. PubMed ID: 17204206
[TBL] [Abstract][Full Text] [Related]
16. Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys.
Lu D; Jin JY; Girish S; Agarwal P; Li D; Prabhu S; Dere RC; Saad OM; Nazzal D; Koppada N; Ramanujan S; Ng CM
Pharm Res; 2015 Jun; 32(6):1907-19. PubMed ID: 25467958
[TBL] [Abstract][Full Text] [Related]
17. The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity.
Abuhay M; Kato J; Tuscano E; Barisone GA; Sidhu RS; O'Donnell RT; Tuscano JM
Cancer Immunol Immunother; 2016 Oct; 65(10):1169-75. PubMed ID: 27506529
[TBL] [Abstract][Full Text] [Related]
18. CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models.
Drake PM; Carlson A; McFarland JM; Bañas S; Barfield RM; Zmolek W; Kim YC; Huang BCB; Kudirka R; Rabuka D
Mol Cancer Ther; 2018 Jan; 17(1):161-168. PubMed ID: 29142069
[TBL] [Abstract][Full Text] [Related]
19. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
20. A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.
Weber T; Mavratzas A; Kiesgen S; Haase S; Bötticher B; Exner E; Mier W; Grosse-Hovest L; Jäger D; Arndt MA; Krauss J
J Immunol Res; 2015; 2015():561814. PubMed ID: 26605343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]